Details

Autor(en) / Beteiligte

• O'Dell, James R
• Mikuls, Ted R
• Taylor, Thomas H
• Ahluwalia, Vandana
• Brophy, Mary
• Warren, Stuart R
• Lew, Robert A
• Cannella, Amy C
• Kunkel, Gary
• Phibbs, Ciaran S
• Anis, Aslam H
• Leatherman, Sarah
• Keystone, Edward

Titel

Therapies for Active Rheumatoid Arthritis after Methotrexate Failure

Ist Teil von

• The New England journal of medicine, 2013-07, Vol.369 (4), p.307-318

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2013

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• In a 48-week trial in patients with active rheumatoid arthritis despite treatment with methotrexate, adding sulfasalazine and hydroxychloroquine to methotrexate was not inferior to adding etanercept. The prognosis for patients with rheumatoid arthritis has improved dramatically over the past two decades. 1 , 2 The reasons for the improved prognosis include earlier diagnosis, treatment targeted to low disease activity or remission, the use of disease-modifying antirheumatic drugs (DMARDs) in combinations, and the availability of biologic therapies. 1 – 4 A substantial portion of patients who are diagnosed today will have a clinical remission with therapy. 1 , 2 , 5 , 6 Unfortunately, the cost of treating rheumatoid arthritis has also risen dramatically, and this disease is now more expensive to treat than diabetes, 7 largely as a consequence of the biologic therapies. Most clinicians . . .